Effective September 26, 2022, Menactra was removed from the ADAP and PrEP‑AP formularies and replaced with MenQuadfi Meningococcal Conjugate Vaccine. The manufacturer Sanofi Pasteur transitioned to MenQuadfi as their sole Meningococcal Conjugate Vaccine in 2022. MenQuadfi is conjugate vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Sanofi Pasteur distributed a provider communication (PDF) that discusses this transition.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP and PrEP-AP drug formularies have been updated to reflect the addition of MenQuadfi.
If you have any questions regarding this update to the ADAP and PrEP-AP formularies, please contact the OA Formulary Specialist, James Vo at James.Vo@cdph.ca.gov.
Sharisse Kemp, MSW
ADAP Branch Chief
California Department of Public Health